Thousands of patients with heart failure are set to benefit from the expansion Thousands of patients with heart failure are set to benefit from the expansion The NHS has announced the expansion of its ...

The new technology was safely trialled on 20 healthy volunteers for the first time ever The new technology was safely trialled on 20 healthy volunteers for the first time ever Researchers at the UK ...

Dr Jonathan Pearce, director, strategy and planning, at UKRI’s Medical Research Council, commented: “This report shows that the UK directed more of its research and innovation activity to COVID-19 ...

The platform will be used to advance the effectiveness of antibiotics The platform will be used to advance the effectiveness of antibiotics Glasgow diagnostics spinout, Microplate Dx, has secured ...

The FDA’s Office of Orphan Drug Products supports the development of treatments for rare disorders that affect fewer than 200,000 people in the US. With the ODD, Faron now has exemption of FDA ...

The EC’s decision allows Abrysvo to be given as a single dose to adults aged 60 years and older, and those who are 32 to 36 weeks into their pregnancy to protect their babies from birth until they are ...

Infex Therapeutics, a company focusing on anti-infectives, has revealed the nomination of a candidate for its COV-X programme.

Avacta – a company developing oncology diagnostics and drugs – has announced that the fifth dose escalation cohort regarding its ALS-6000 candidate. The phase 1 research was evaluating the ...

Novartis has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Cosentyx – also known as secukinumab.

XBiotech has announced the enrolment of the first patient in a multicentre, randomised clinical study for Natrunix. The treatment will be analysed in combination with trifluridine and tipiracil for ...

AbbVie has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Rinvoq (upadacitinib).

Scientists demonstrated that AZD1236 halts oedema while reducing spinal cord breakdown at the site of the injury Research from the University of Birmingham has shown that an existing drug may reduce ...